Premium
Early identification of Epstein‐Barr virus‐associated post‐transplantation lymphoproliferative disease
Author(s) -
Rooney Cliona M.,
Loftin Susan K,
Holladay Martha S.,
Brenner Malcolm K.,
Krance Robert A.,
Heslop Helene E.
Publication year - 1995
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1995.tb08904.x
Subject(s) - medicine , epstein–barr virus , transplantation , lymphoproliferative disorders , disease , immunology , virus , lymphoproliferative disease , human leukocyte antigen , bone marrow , post transplant lymphoproliferative disorder , herpesviridae , viral disease , lymphoma , antigen
Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD) is a common, usually fatal, complication developing after transplantation of bone marrow from HLA-mismatched or HLA-matched unrelated donors. Prompted by recent reports of successful treatment of EBV-LPD, we investigated methods which could result in early identification of patients at high risk for this disorder, thus improving the likelihood of successful therapeutic interventions. Both the outgrowth of transformed B lymphocytes ex vivo (100% correlation) and the detection of EBV DNA by a PCR method (80% correlation) showed statistically significant association with the histopathological diagnosis of EBV-LPD. Because these abnormalities can be detected prior to the onset of clinical disease. It should now be possible to use a combination of the methods described here to identify patients at high risk of developing EBV-LPD, thus enabling early therapeutic intervention.